TY - JOUR
T1 - A (+)-Larixol Congener with High Affinity and Subtype Selectivity toward TRPC6
AU - Häfner, Stephanie
AU - Burg, Finn
AU - Kannler, Martina
AU - Urban, Nicole
AU - Mayer, Peter
AU - Dietrich, Alexander
AU - Trauner, Dirk
AU - Broichhagen, Johannes
AU - Schaefer, Michael
N1 - Funding Information:
D.T. and J.B. thank the Munich Center for Integrated Protein Science (CIPSM). This work was supported by the SFB TRR 152 (S.H., D.T., J.B., and M.S.). D.T. acknowledges support of the European Research Council for an Advanced Grant (268795). We thank Dominik Dosch for synthetic assistance, and Narges Pourmandi for proofreading.
Publisher Copyright:
© 2018 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim
PY - 2018/5/23
Y1 - 2018/5/23
N2 - Natural products have many health benefits, and their application can improve the quality of life. Recently, the diterpene (+)-larixol and its acetylated congeners demonstrated selective inhibition of the second-messenger-gated cation channel transient receptor potential canonical 6 (TRPC6) over its close isoforms TRPC3 and TRPC7. Building on this knowledge, we expanded these findings by chemical diversification of (+)-larixol mostly at position C6. Implementing high-throughput Ca2+ FLIPR screening assays and electrophysiological patch-clamp recordings, we showcase larixyl N-methylcarbamate, termed SH045, as a compound with nanomolar affinity and 13-fold subtype selectivity over TRPC3 in stably expressing HEK293 cells. Expanding on this finding, TRPC6 inhibition was also observed in rat pulmonary smooth muscle cells. Furthermore, treatment of isolated perfused lung preparations with SH045 led to a decrease in lung ischemia-reperfusion edema (LIRE), a life-threatening condition associated with TRPC6 that may occur after organ transplantation. Taken together, and given the inexpensive, straightforward, and scalable preparation of SH045, we report a TRPC6 blocker that holds promise for the translational treatment of LIRE.
AB - Natural products have many health benefits, and their application can improve the quality of life. Recently, the diterpene (+)-larixol and its acetylated congeners demonstrated selective inhibition of the second-messenger-gated cation channel transient receptor potential canonical 6 (TRPC6) over its close isoforms TRPC3 and TRPC7. Building on this knowledge, we expanded these findings by chemical diversification of (+)-larixol mostly at position C6. Implementing high-throughput Ca2+ FLIPR screening assays and electrophysiological patch-clamp recordings, we showcase larixyl N-methylcarbamate, termed SH045, as a compound with nanomolar affinity and 13-fold subtype selectivity over TRPC3 in stably expressing HEK293 cells. Expanding on this finding, TRPC6 inhibition was also observed in rat pulmonary smooth muscle cells. Furthermore, treatment of isolated perfused lung preparations with SH045 led to a decrease in lung ischemia-reperfusion edema (LIRE), a life-threatening condition associated with TRPC6 that may occur after organ transplantation. Taken together, and given the inexpensive, straightforward, and scalable preparation of SH045, we report a TRPC6 blocker that holds promise for the translational treatment of LIRE.
KW - LIRE
KW - TRPC6
KW - diterpenes
KW - labdane
KW - larixol
UR - http://www.scopus.com/inward/record.url?scp=85045874516&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85045874516&partnerID=8YFLogxK
U2 - 10.1002/cmdc.201800021
DO - 10.1002/cmdc.201800021
M3 - Article
C2 - 29522264
AN - SCOPUS:85045874516
SN - 1860-7179
VL - 13
SP - 1028
EP - 1035
JO - ChemMedChem
JF - ChemMedChem
IS - 10
ER -